BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity
L. C. Wellinger, S. J. Hogg, D. M. Newman, T. Friess, D. Geiss, J. Michie, K. M. Ramsbottom, M. Bacac, T. Fauti, D. Marbach, L. Jarassier, P. Thienger, A. Paehler, L. A. Cluse, C. J. Kearney, , R. W. Johnstone
This paper identifies BET bromodomain inhibitors as agents that enhance anti-tumor immunity by sensitizing tumors to TNF-mediated cytotoxicity through suppression of NF-κB signaling.
bioRxiv · Feb 15, 2021Cancer Biology